Everything below concerns PT-141. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Methylglyoxal (MGO) is the organic compound with the formula CH3C(O)CHO. It is a reduced derivative of pyruvic acid. It is a reactive compound that is implicated in the biology of diabetes. Methylglyoxal is produced industrially by degradation of carbohydrates using overexpressed methylglyoxal synthase.
=== Clinical trials and early approvals for diabetes === In June 2008, a phase II clinical trial began studying semaglutide, a once-weekly diabetes therapy as a longer-acting alternative to liraglutide. It was given the brand name Ozempic. Clinical trials started in January 2016 and ended in May 2017. The US Food and Drug Administration (FDA) approved semaglutide based on evidence from seven clinical trials of 4087 participants with type 2 diabetes. The trials were conducted at 536 sites in 33 countries, including Canada, Mexico, Russia, Ukraine, Turkey, India, South Africa, Japan, Hong Kong, multiple European countries, Argentina, and the United States. In two of these trials (NCT02054897 and NCT02305381), participants were randomly assigned to receive either semaglutide or placebo injection weekly. Neither the participant nor the health care provider knew which treatment was being given until after the trials were completed. Treatment was given for 30 weeks. In the other five trials (NCT01930188, NCT01885208, NCT02128932, NCT02207374, and NCT02254291), participants were randomly assigned to receive either semaglutide or another anti-diabetic medication, and the participant and provider knew which medication was being given in four trials. Treatment was given for 30 weeks or 56 weeks. In each trial, HbA1c was measured from the start of the trial to the end of the trial and compared between the semaglutide group and the other groups.
Another example is Girgui at Harvard University, who built a MMS based on existing underwater mass spectrometers (UMS) that can operate underwater to study the influence of microbes on the methane and hydrogen content of the ocean. He worked with a mechanical engineer to package a commercial quadrupole mass analyzer from Stanford Research Systems, a Pfeiffer HiPace80 turbopump, and a custom gas extractor into a 25 cm × 90 cm cylinder. Total cost is about $15,000. The Analytical Instrumentation Research Institute in Korea also developed a palm-portable mass spectrometer. The size and weight is reduced to 1.54 L and 1.48 kg respectively, and it used 5 W power only. The PPMS is based on four parallel disk ion traps, a small ion getter pump and a micro-computer. The PPM can perform the scan ion mass of up to m/z 300 and detect the ppm concentration of organic gases diluted in the air. The Harsh-Environment Mass Spectrometry Society is holding a biannual workshop that focuses on in-situ mass spectrometry in extreme environments, such as in the deep ocean, volcano crater, or outer space require high reliability, autonomous or remote operation, ruggedness with minimum size, weight, and power. The archives of the workshop include ~100 presentations focusing on the design and application of miniature mass spectrometers.
Sources: en.wikipedia.org
In June 1884, Jan Gerrit Bantjes (1843–1914) discovered signs of gold at Vogelstruisfontein (the first gold sold directly to Cecil Rhodes at Bantjes's camp for £3,000) followed in September by the Struben brothers at Wilgespruit near Roodepoort which started the Witwatersrand Gold Rush and modern-day Johannesburg. The first gold mines of the Witwatersrand were the Bantjes Consolidated Mines. By 1886 it was clear that there were massive deposits of gold in the main reef. Increasingly Uitlanders (non-Afrikaner European expatriates and settlers, mainly from Britain but also including other Europeans, Americans and Australians), had come into the republic in search of employment and fortune. The discovery of gold made the Transvaal overnight the richest and potentially the most powerful nation in southern Africa, but it attracted so many Uitlanders (in 1896 approximately 60,000) that they quickly outnumbered the Boers (approximately 30,000 white male Boers). Fearful of the Transvaal's losing independence and becoming a British colony, the Boer government adopted policies of protectionism and exclusion, to include restrictions requiring Uitlanders to be resident for at least four years in the Transvaal to obtain the franchise, or right to vote. They heavily taxed the growing gold mining industry which was more dominated by incoming Uitlanders. Due to this taxation, the Uitlanders became increasingly resentful and aggrieved about the lack of representation.
polypeptide A long, continuous, and unbranched polymeric chain of amino acid monomers linked by covalent peptide bonds, typically longer than a peptide. Proteins generally consist of one or more polypeptides folded or arranged in a biologically functional way.
In 1911, Tolkien went on a summer holiday in Switzerland, a trip that he recollected vividly in a 1968 letter, noting that Bilbo's journey across the Misty Mountains ("including the glissade down the slithering stones into the pine woods") is directly based on his adventures as their party of 12 hiked from Interlaken to Lauterbrunnen and on to camp in the moraines beyond Mürren. Fifty-seven years later, Tolkien remembered his regret at leaving the view of the eternal snows of Jungfrau and Silberhorn, "the Silvertine (Celebdil) of my dreams". They went across the Kleine Scheidegg to Grindelwald and on across the Grosse Scheidegg to Meiringen. They continued across the Grimsel Pass, through the upper Valais to Brig and on to the Aletsch glacier and Zermatt. In October of the same year, Tolkien began studying at Exeter College, Oxford. He initially read classics but changed his course in 1913 to English language and literature, graduating in 1915 with first-class honours. Among his tutors at Oxford was Joseph Wright, whose Primer of the Gothic Language had inspired Tolkien as a schoolboy.
Sources: en.wikipedia.org
== History == α-MSH was first isolated in the 1950s and its primary structure determined. By the 1960s, its role in promoting melanin diffusion was understood. In the 1980s, the University of Arizona synthesised more potent analogs of a-MSH, including afamelanotide. Afamelanotide was initially named melano-tan (or melanotan-I) due to its ability to tan skin with minimal sun exposure. Later, melanotan-II was synthesised. Following initial development at the University of Arizona as a sunless tanning agent, the Australian company Clinuvel conducted further clinical trials in that and other indications, and brought the drug to market in the European Union, the United States, and Australia. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. Early clinical trials showed that the peptide had to be injected about ten times a day due to its short half-life, so the company collaborated with Southern Research in the US to develop a depot formulation that would be injected under the skin, and release the peptide slowly. This was done by 2004. Multiple studies on the clinical effects of afamelanotide were conducted. According to ClinicalTrials.gov, Clinuvel sponsored several trials between 2007 and 2011 to explore its effects on erythropoietic protoporphyria, vitiligo, polymorphous light eruption, solar urticaria and acne vulgaris.
lipid Any of a heterogeneous class of organic compounds, including glycerides (fats), waxes, sterols, and some vitamins, united only by their amphipathic or hydrophobic nature and consequently their very low solubility in water. Some lipids such as phospholipids tend to form lamellar structures or micelles in aqueous environments, where they serve as the primary constituents of biological membranes. Others such as fatty acids can be metabolized for energy, have important functions in energy storage, or serve as signaling molecules. Colloquially, the term "lipids" is sometimes used as a synonym for fats, though fats are more correctly considered a subclass of lipids.
The goal of substituting DNA by XNA may also be reached by another route, namely by engineering the environment instead of the genetic modules. This approach has been successfully demonstrated by Marlière and Mutzel with the production of an E. coli strain whose DNA is composed of standard A, C and G nucleotides but has the synthetic thymine analogue 5-chlorouracil instead of thymine (T) in the corresponding positions of the sequence. These cells are then dependent on externally supplied 5-chlorouracil for growth, but otherwise they look and behave as normal E. coli. These cells, however, are currently not yet fully auxotrophic for the Xeno-base since they are still growing on thymine when this is supplied to the medium.
coli and Saccharomyces cerevisiae in a consortium could be used as industrial microbes to produce precursors of the chemotherapeutic agent paclitaxel by applying the metabolic engineering in a co-culture approach to exploit the benefits from the two microbes. Another example of synthetic biology applications in industrial biotechnology is the re-engineering of the metabolic pathways of E. coli by CRISPR and CRISPRi systems toward the production of a chemical known as 1,4-butanediol, which is used in fiber manufacturing. In order to produce 1,4-butanediol, the authors alter the metabolic regulation of the Escherichia coli by CRISPR to induce point mutation in the gltA gene, knockout of the sad gene, and knock-in six genes (cat1, sucD, 4hbd, cat2, bld, and bdh). Whereas CRISPRi system used to knockdown the three competing genes (gabD, ybgC, and tesB) that affect the biosynthesis pathway of 1,4-butanediol. Consequently, the yield of 1,4-butanediol significantly increased from 0.9 to 1.8 g/L.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.